GLOW is a three-component preparation supplying GHK-Cu, BPC-157 and TB-500 in a single vial.
The three components
GHK-Cu is a copper-binding tripeptide acting on dermal fibroblasts, stimulating collagen and elastin synthesis and modulating matrix turnover. Covered in detail in our GHK-Cu guide.
BPC-157 is a pentadecapeptide with no known dedicated receptor, associated with VEGFR2 signalling and angiogenesis. See our BPC-157 guide.
TB-500 is a synthetic fragment of thymosin beta-4, the principal actin-sequestering protein in mammalian cells. Research describes effects on actin dynamics, cell migration and angiogenesis.
What a blend means methodologically
This is the part worth stating plainly. Three mechanisms in one vial is convenient, but it makes attribution difficult: the combination has not been characterised as a single pharmacological entity, and component interactions are not described in the literature.
If a research design needs to know which mechanism produced an observed effect, single-compound preparations are the appropriate tool. A blend is suited to work where several signalling arms are examined in parallel and attribution is not the question being asked.
Supplied lyophilised. See our reconstitution protocol for handling technique and diluent selection.
Every batch ships with a third-party certificate of analysis. View GLOW and its current COA.
Research use only
Isla Longevity supplies this compound for laboratory research use only. It is not approved by the FDA for human or veterinary use and is not for human consumption. This article summarises published research and is not medical guidance.
